BioXmark® publications

Clinical studies

Ciernik IF, Greiss AM. Visualization of the tumor cavity after lumpectomy of breast cancer for postoperative radiotherapy. Clinical and Translational Radiation Oncology. 2019 Jan; 14:47–50.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279963/
de Blanck SR, Rydhög JS, Larsen KR, Clementsen PF, Josipovic M, Aznar MC, af Rosenschöld PM, Jølck RI, Specht L, Andresen TL, Persson GF. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology. 2018 Nov; 13:24–8.
https://pubmed.ncbi.nlm.nih.gov/30258990/
de Blanck SR, Scherman-Rydhög J, Siemsen M, Christensen M, Baeksgaard L, Irming Jølck R, Specht L, Andresen TL, Persson GF. Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of esophageal cancer. Br J Radiol. 2018 Dec;91(1092):20180236.
https://pubmed.ncbi.nlm.nih.gov/29975152/
de Ridder M, Gerbrandy LC, de Reijke TM, Hinnen KA, Hulshof MCCM. BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. BJR. 2020 Jun 1;20200241.
https://www.birpublications.org/doi/abs/10.1259/bjr.20200241
Machiels M, Voncken FEM, Jin P, Dieren JM van, Bartels-Rutten A, Alderliesten T, Aleman BMP, Hooft JE van, Hulshof MCCM. A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Practical Radiation Oncology. 2019 Nov 1;9(6): e506–15.
https://pubmed.ncbi.nlm.nih.gov/31279938/
Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølck RI, Josipovic M, Aznar MC, Specht L, Andresen TL, Rosenschöld PM af, Persson GF. Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiotherapy and Oncology. 2016 Oct;121(1):64–9.
https://pubmed.ncbi.nlm.nih.gov/27443450/
Rydhög Scherman J, Perrin R, Jølck RI, Gagnon-Moisan F, Larsen KR, Clementsen P, Riisgaard de Blanck S, Fredberg Persson G, Weber DC, Lomax T, Andresen TL, Munck af Rosenschold P. Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology. 2017 Mar;122(3):393–9.
https://pubmed.ncbi.nlm.nih.gov/28104299/
Scherman Rydhög J, Riisgaard de Blanck S, Josipovic M, Irming Jølck R, Larsen KR, Clementsen P, Lars Andersen T, Poulsen PR, Fredberg Persson G, Munck af Rosenschold P. Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiotherapy and Oncology. 2017 Apr;123(1):78–84.
https://www.ncbi.nlm.nih.gov/pubmed/28245908

Non clinical studies

Bertholet J, Knopf A, Eiben B, McClelland J, Grimwood A, Harris E, Menten M, Poulsen P, Nguyen DT, Keall P, Oelfke U. Real-time intrafraction motion monitoring in external beam radiotherapy. Phys Med Biol. 2019 Aug;64(15):15TR01.
https://pubmed.ncbi.nlm.nih.gov/31226704/
Brown KH, Ghita M, Schettino G, Prise KM, Butterworth KT. Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications.
https://pubmed.ncbi.nlm.nih.gov/32443537/
Clerc-Renaud B, Boss M-K, Griffin LR, LaRue SM, Leary D. Potential for BioXmark liquid fiducial marker to improve identification of superficial component of canine oral tumors for computer-based radiation therapy planning. Can Vet J. 2019 Oct;60(10):1072–80.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741831/
De Roover R, Crijns W, Poels K, Peeters R, Draulans C, Haustermans K, Depuydt T. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. Med Phys. 2018 May;45(5):2205–17.
https://www.ncbi.nlm.nih.gov/pubmed/29537613
Dobiasch S, Kampfer S, Burkhardt R, Schilling D, Schmid TE, Wilkens JJ, Combs SE. BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid fiducial marker. Strahlenther Onkol. 2017 Dec;193(12):1039–47.
https://www.ncbi.nlm.nih.gov/pubmed/28808749
Hamming VC, Brouwer CL, Van Goethem MJ, Jolck RI, Van Leijsen C, Van den Bergh ACM. PO-0866: Visibility, image artifacts and proton dose perturbation of fiducial markers. Radiotherapy and Oncology. 2017 May;123:S471–2.
https://www.thegreenjournal.com/article/S0167-8140(17)31303-8/pdf
Jelvehgaran P, Alderliesten T, Weda JJA, de Bruin M, Faber DJ, Hulshof MCCM, van Leeuwen TG, van Herk M, de Boer JF. Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study. Med Phys. 2017 Dec;44(12):6570–82.
https://www.ncbi.nlm.nih.gov/pubmed/29023771
Mortensen SR, Scherman JB, Larsen KR, Jølck RI, Persson GF, Hansen AE, Eriksen T, Specht L. Use of a Novel Liquid Fiducial Marker Injected With Endoscopic Ultrasound Equipment for Use in Image Guided Radiation Therapy of Thoracic Tumors (Porcine Model). International Journal of Radiation Oncology • Biology • Physics. 2014 Sep 1;90(1): S651.
http://www.redjournal.org/article/S0360-3016(14)02577-2/abstract
Rydhög JS, Jølck RI, Andresen TL, Rosenschöld PM af. PO-0964: Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR. Radiotherapy and Oncology. 2015 Apr 1;115: S510.
http://nanovi.com/wp-content/uploads/2015/05/Rydhög-J-et-al.-poster.pdf
Scherman JR, Irming Jølck R, Andresen TL, Munck af Rosenschöld P. Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy: A new liquid fiducial marker for IGRT. Med Phys. 2015 May 15;42(6Part1):2818–26.
https://www.ncbi.nlm.nih.gov/pubmed/26127034
Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL. Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI. Strahlenther Onkol. 2019 Aug;195(8):756–63.
https://pubmed.ncbi.nlm.nih.gov/31143995/
Schneider S, Jølck RI, Troost EGC, Hoffmann AL. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom. Med Phys. 2018 Jan;45(1):37–47.
https://www.ncbi.nlm.nih.gov/pubmed/29136287
Troost E, Menkel S, Enghardt W, Hytry J, Kunath D, Makocki S, Hoffmann A, Jølck R. EP-1710: Chemical stability of BioXmark® following normofractionated and single-fraction proton beam therapy. Radiotherapy and Oncology. 2017 May 1;123:S937–8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6871657/
Hafeez S, Hansen VN, McNair H, Harris E, Jones K, Schmidt M, Kumar P, Huddart R. Assessing feasibility of a new fundicial marker (BioXmark) for bladder tumor localization and position verification during radical radiotherapy in a porcine phantom. Abstract 30th EUS Annual Meeting, New Orleans, LA, 2015 May 16.
http://engineering-urology.org/am/30EUS_2015.pdf (Abstract 8; P: 22)

   Complete BioXmark® publication list:   BioXmark® publication list